Wang Jing, Huang Liwei, Chen Xi, Yuan Yangchen, Sun Juan, Yang Meng
School of Pharmaceutical Engineering, Jiangsu Food & Pharmaceutical Science College.
School of Biological & Chemical Engineering, Zhejiang University of Science & Technology.
Chem Pharm Bull (Tokyo). 2022;70(9):637-641. doi: 10.1248/cpb.c22-00303.
Human epidermal growth factor (EGFR) is an important target for antitumor drug research. A series of novel quinazolinone derivatives were synthesized and developed as potent inhibitors of EGFR. The results showed that most of the aimed compounds had potential anti-tumor cell proliferation activities. Some compounds were tested for their EGFR inhibitory activity. Especially, compound 6d showed the most potent antitumor activity with IC values of 1.58 µM against human breast cancer (MCF-7) cell lines and exhibited the most potent EGFR inhibitory activity with IC of 0.77 µM. Docking simulation was performed to position compound 6d into the EGFR active site to determine the probable binding conformation.
人表皮生长因子(EGFR)是抗肿瘤药物研究的重要靶点。合成并开发了一系列新型喹唑啉酮衍生物作为EGFR的强效抑制剂。结果表明,大多数目标化合物具有潜在的抗肿瘤细胞增殖活性。对一些化合物进行了EGFR抑制活性测试。特别是,化合物6d表现出最有效的抗肿瘤活性,对人乳腺癌(MCF-7)细胞系的IC值为1.58 µM,并且表现出最有效的EGFR抑制活性,IC值为0.77 µM。进行对接模拟以将化合物6d定位到EGFR活性位点,以确定可能的结合构象。